/term/net-income-including-noncontrolling-interests/OCS OCS (Oculis Holding AG) Net Income Including Noncontrolling
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Net Income Including Noncontrolling Interests

Oculis Holding AG (Oculis Holding AG) Net Income Including Noncontrolling Interests : $-66.22 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Oculis Holding AG's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was $-18.11 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was $-66.22 Mil.


Oculis Holding AG Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Oculis Holding AG's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Net Income Including Noncontrolling Interests Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
-16.74 -20.14 -41.54 -102.69

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.72 -14.30 -19.36 -14.45 -18.11

Oculis Holding AG Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (Oculis Holding AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Net Income Including Noncontrolling Interests
Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (Oculis Holding AG) Headlines

From GuruFocus

Oculis to Participate in Jefferies Healthcare Conference

By sperokesalga sperokesalga 06-01-2023

Oculis to Participate and Present at Upcoming EuDES Meeting

By sperokesalga sperokesalga 05-24-2023